First Annual
ADDF/Élan
Awards Luncheon
January 26, 2006
Lotos Club, New York City
The Alzheimer's Drug Discovery Foundation, a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Lauder family in 1998, and Élan Pharmaceuticals, Inc., a neuroscience-based biotechnology company, are pleased to announce the winners of their new research award program, Novel Approaches to Drug Discovery for Alzheimer’s Disease. Four recipients were selected from a highly competitive pool of 45 scientists from 12 countries.
The
award-winners are Steven S. Schreiber, PhD, Professor of Neurology and
Anatomy and Neurobiology at the University of California Irvine School of
Medicine; Greg R. J. Thatcher, PhD, Professor of Medicinal Chemistry at
the University of Illinois at Chicago; Nicholas Webster, PhD, Professor
in Residence at University of California, San Diego; and
Berislav Zlokovic,
PhD, Professor and Associate Chair of Neurosurgery at the University of
Rochester Medical Center. They were chosen by an independent scientific review
panel of 10 experts chaired by ADDF Executive Director Howard Fillit, MD, a
leading geriatrician and neuroscientist.
The
scientists received their awards at a recent luncheon held in New York City. Mr.
Leonard Lauder, ADDF Co-Chairperson and Chairman of the Estée
Lauder Companies Inc., and Mr. Kelly Martin, Élan President and CEO,
welcomed an audience of over 40 distinguished guests to celebrate the
inauguration of the first annual ADDF/Élan Alzheimer’s Disease Drug
Discovery Awards and to recognize the recipients. During the luncheon, Mr.
Lauder and Mr. Martin both commented on the importance of this program and the
ongoing need to accelerate the discovery of effective drugs to conquer one of
the most devastating diseases of the 21st Century. This disease
affects 1 out of 3 people over the age of 80.